Substantial Decrease in Comorbidity 5 Years After Gastric Bypass: A Population-based Study From the Scandinavian Obesity Surgery Registry

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Substantial Decrease in Comorbidity 5 Years After Gastric Bypass : A Population-based Study From the Scandinavian Obesity Surgery Registry. / Sundbom, Magnus; Hedberg, Jakob; Marsk, Richard; Boman, Lars; Bylund, Ami; Hedenbro, Jan; Laurenius, Anna; Lundegårdh, Göran; Möller, Peter; Olbers, Torsten; Ottosson, Johan; Näslund, Ingmar; Näslund, Erik.

I: Annals of Surgery, Vol. 265, Nr. 6, 2017, s. 1166-1171.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Sundbom, M, Hedberg, J, Marsk, R, Boman, L, Bylund, A, Hedenbro, J, Laurenius, A, Lundegårdh, G, Möller, P, Olbers, T, Ottosson, J, Näslund, I & Näslund, E 2017, 'Substantial Decrease in Comorbidity 5 Years After Gastric Bypass: A Population-based Study From the Scandinavian Obesity Surgery Registry', Annals of Surgery, vol. 265, nr. 6, s. 1166-1171. https://doi.org/10.1097/SLA.0000000000001920

APA

CBE

Sundbom M, Hedberg J, Marsk R, Boman L, Bylund A, Hedenbro J, Laurenius A, Lundegårdh G, Möller P, Olbers T, Ottosson J, Näslund I, Näslund E. 2017. Substantial Decrease in Comorbidity 5 Years After Gastric Bypass: A Population-based Study From the Scandinavian Obesity Surgery Registry. Annals of Surgery. 265(6):1166-1171. https://doi.org/10.1097/SLA.0000000000001920

MLA

Vancouver

Author

Sundbom, Magnus ; Hedberg, Jakob ; Marsk, Richard ; Boman, Lars ; Bylund, Ami ; Hedenbro, Jan ; Laurenius, Anna ; Lundegårdh, Göran ; Möller, Peter ; Olbers, Torsten ; Ottosson, Johan ; Näslund, Ingmar ; Näslund, Erik. / Substantial Decrease in Comorbidity 5 Years After Gastric Bypass : A Population-based Study From the Scandinavian Obesity Surgery Registry. I: Annals of Surgery. 2017 ; Vol. 265, Nr. 6. s. 1166-1171.

RIS

TY - JOUR

T1 - Substantial Decrease in Comorbidity 5 Years After Gastric Bypass

T2 - A Population-based Study From the Scandinavian Obesity Surgery Registry

AU - Sundbom, Magnus

AU - Hedberg, Jakob

AU - Marsk, Richard

AU - Boman, Lars

AU - Bylund, Ami

AU - Hedenbro, Jan

AU - Laurenius, Anna

AU - Lundegårdh, Göran

AU - Möller, Peter

AU - Olbers, Torsten

AU - Ottosson, Johan

AU - Näslund, Ingmar

AU - Näslund, Erik

PY - 2017

Y1 - 2017

N2 - OBJECTIVE:: To evaluate effect on comorbid disease and weight loss 5 years after Roux-en-Y gastric bypass (RYGB) surgery for morbid obesity in a large nationwide cohort. BACKGROUND:: The number patients having surgical procedures to treat obesity and obesity-related disease are increasing. Yet, population-based, long-term outcome studies are few. METHODS:: Data on 26,119 individuals [75.8% women, 41.0 years, and body mass index (BMI) 42.8?kg/m] undergoing primary RYGB between May 1, 2007 and June 30, 2012, were collected from 2 Swedish quality registries: Scandinavian Obesity Surgery Registry and the Prescribed Drug Registry. Weight, remission of type 2 diabetes mellitus, hypertension, dyslipidemia, depression, and sleep apnea, and changes in corresponding laboratory data were studied. Five-year follow-up was 100% (9774 eligible individuals) for comorbid diseases. RESULTS:: BMI decreased from 42.8?±?5.5 to 31.2?±?5.5?kg/m at 5 years, corresponding to 27.7% reduction in total body weight. Prevalence of type 2 diabetes mellitus (15.5%–5.9%), hypertension (29.7%–19.5%), dyslipidemia (14.0%–6.8%), and sleep apnea (9.6%–2.6%) was reduced. Greater weight loss was a positive prognostic factor, whereas increasing age or BMI at baseline was a negative prognostic factor for remission. The use of antidepressants increased (24.1%–27.5%). Laboratory status was improved, for example, fasting glucose and glycated hemoglobin decreased from 6.1 to 5.4?mmol/mol and 41.8% to 37.7%, respectively. CONCLUSIONS:: In this nationwide study, gastric bypass resulted in large improvements in obesity-related comorbid disease and sustained weight loss over a 5-year period. The increased use of antidepressants warrants further investigation.

AB - OBJECTIVE:: To evaluate effect on comorbid disease and weight loss 5 years after Roux-en-Y gastric bypass (RYGB) surgery for morbid obesity in a large nationwide cohort. BACKGROUND:: The number patients having surgical procedures to treat obesity and obesity-related disease are increasing. Yet, population-based, long-term outcome studies are few. METHODS:: Data on 26,119 individuals [75.8% women, 41.0 years, and body mass index (BMI) 42.8?kg/m] undergoing primary RYGB between May 1, 2007 and June 30, 2012, were collected from 2 Swedish quality registries: Scandinavian Obesity Surgery Registry and the Prescribed Drug Registry. Weight, remission of type 2 diabetes mellitus, hypertension, dyslipidemia, depression, and sleep apnea, and changes in corresponding laboratory data were studied. Five-year follow-up was 100% (9774 eligible individuals) for comorbid diseases. RESULTS:: BMI decreased from 42.8?±?5.5 to 31.2?±?5.5?kg/m at 5 years, corresponding to 27.7% reduction in total body weight. Prevalence of type 2 diabetes mellitus (15.5%–5.9%), hypertension (29.7%–19.5%), dyslipidemia (14.0%–6.8%), and sleep apnea (9.6%–2.6%) was reduced. Greater weight loss was a positive prognostic factor, whereas increasing age or BMI at baseline was a negative prognostic factor for remission. The use of antidepressants increased (24.1%–27.5%). Laboratory status was improved, for example, fasting glucose and glycated hemoglobin decreased from 6.1 to 5.4?mmol/mol and 41.8% to 37.7%, respectively. CONCLUSIONS:: In this nationwide study, gastric bypass resulted in large improvements in obesity-related comorbid disease and sustained weight loss over a 5-year period. The increased use of antidepressants warrants further investigation.

UR - http://www.scopus.com/inward/record.url?scp=84978766634&partnerID=8YFLogxK

U2 - 10.1097/SLA.0000000000001920

DO - 10.1097/SLA.0000000000001920

M3 - Article

VL - 265

SP - 1166

EP - 1171

JO - Annals of Surgery

JF - Annals of Surgery

SN - 1528-1140

IS - 6

ER -